1 in 5 Australians live with incurable eczema1. Yet many patients are confused by the nature of the disease, searching for a management plan to appropriately look after their chronic dry skin2.
As the first point of contact for up to 70% of eczema patients, be the one to add value3 and Get Eczema Managed with Ego’s 6-part Eczema Educational Series.
Bite sized modules unpacking the underlying causes of eczema and key management approaches to fuel pharmacists like yourself, with knowledge and confidence to help your patients manage eczema and achieve greater clinical outcomes.
A module will drop bi-monthly to keep you in the loop on best practice. Topics include;
Watch this space!
Eczema 101
As the first point of contact for many eczema sufferers3, un-packing the basics of eczema and understanding the integral function of the skin may help better assess your patient’s symptoms.
Eczema 101
As the first point of contact for many eczema sufferers3, un-packing the basics of eczema and understanding the integral function of the skin may help better assess your patient’s symptoms.
The Eczema Management Plan
Executing an Eczema Management Plan successfully can be challenging in practise. The module outlines sequential components of a proactive and efficient plan and provides guidance on implementing it effectively with your customers.
The Eczema Management Plan
Executing an Eczema Management Plan successfully can be challenging in practise. The module outlines sequential components of a proactive and efficient plan and provides guidance on implementing it effectively with your customers.
Step 1: The Role of Topical Corticosteroids
Topical corticosteroids have been the cornerstone of eczema management for years, however ‘corticosteroid phobia’ is impacting patient compliance and increased duration of the disease. Learn how recommending the right topical corticosteroid affects the rate of healing and dispels customer misconceptions.
Step 1: The Role of Topical Corticosteroids
Topical corticosteroids have been the cornerstone of eczema management for years, however ‘corticosteroid phobia’ is impacting patient compliance and increased duration of the disease. Learn how recommending the right topical corticosteroid affects the rate of healing and dispels customer misconceptions.
Step2: Moisturisers
As the second step of the eczema management plan, learn about the role of moisturisers in ongoing skin maintenance and how they can be used in combination with topical corticosteroids (TCS) as part of an effective eczema management plan.
Step2: Moisturisers
As the second step of the eczema management plan, learn about the role of moisturisers in ongoing skin maintenance and how they can be used in combination with topical corticosteroids (TCS) as part of an effective eczema management plan.
Debunking Eczema Management Myths
There are some long held myths amongst both patients and health professionals surrounding the use of TCS and emollients for eczema. This module investigate some of these misconceptions and arm pharmacists with the tools necessary to separate the facts from the fiction when it comes to eczema management.
Debunking Eczema Management Myths
There are some long held myths amongst both patients and health professionals surrounding the use of TCS and emollients for eczema. This module investigate some of these misconceptions and arm pharmacists with the tools necessary to separate the facts from the fiction when it comes to eczema management.
Together we can achieve a reduction in eczema severity for your patients. Learn more about Ego’s Eczema Management Plan and tailored approach.
1. Kantar TNS. Online mini-poll on eczema. 2019. Australia. (n=306). Sponsored by Ego Pharmaceuticals Pty Ltd. Result based on response to question ‘Does anyone in your household suffer from eczema?’.
2. Atopic Dermatitis Australian Study. Study sponsored by Sanofi Australia. 2018; 1(4).
3. Kantar Health. Mini Health professional poll. 2017. Australia. (n=15). Sponsored by Ego Pharmaceuticals Pty Ltd. Result based ‘Level of involvement of HCPs during patient journey.’
